Long-term treatment of venous thromboembolism
… thrombosis, proximal This review focuses on the long-term treatment of leg deep vein
thrombosis (DVT) and pulmonary embolism (PE) and does not include arm DVT or venous …
thrombosis (DVT) and pulmonary embolism (PE) and does not include arm DVT or venous …
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐and low‐dose rivaroxaban with aspirin
K Boonyawat, AWA Lensing, MH Prins… - … in thrombosis and …, 2021 - Wiley Online Library
… rivaroxaban 20 mg, rivaroxaban 10 mg, and aspirin 100 mg for extended treatment of venous
thromboembolism in patients who had completed 6 to 12 months of anticoagulant therapy. …
thromboembolism in patients who had completed 6 to 12 months of anticoagulant therapy. …
Anticoagulation for patients with venous thromboembolism: when is extended treatment required?
JI Weitz, P Prandoni, P Verhamme - TH Open, 2020 - thieme-connect.com
… of anticoagulant therapy, the need for extended treatment is usually determined by balancing
the risk of recurrence if treatment is stopped against the risk of bleeding if treatment is …
the risk of recurrence if treatment is stopped against the risk of bleeding if treatment is …
[HTML][HTML] Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study
D Imberti, F Pomero, D Mastroiacovo - Blood Transfusion, 2020 - ncbi.nlm.nih.gov
… These new findings on extended therapy suggest the possibility of anticoagulation regimens
… VTE characteristics, with a shift of the risk-benefit balance in favour of extended treatment. …
… VTE characteristics, with a shift of the risk-benefit balance in favour of extended treatment. …
… randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post …
C Bradbury, K Fletcher, Y Sun… - British Journal of …, 2020 - Wiley Online Library
… Anticoagulation therapy (AT) remains the mainstay of treatment for VTE. Clinical guidelines
… deep vein thrombosis (DVT) or pulmonary embolism (PE), with consideration of long-term, …
… deep vein thrombosis (DVT) or pulmonary embolism (PE), with consideration of long-term, …
Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis
B Hu, L Jiang, H Tang, M Hu, J Yu, Z Dai - Journal of Orthopaedic Surgery …, 2021 - Springer
… Rivaroxaban is the world’s first oral inhibitor of factor Xa. It is used to prevent and treat venous
thromboembolism and prevent stroke or systemic embolism in atrial fibrillation [19]. It has …
thromboembolism and prevent stroke or systemic embolism in atrial fibrillation [19]. It has …
[HTML][HTML] … ‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism …
… anticoagulation, estimates from this study could be used to determine the net clinical
benefit of extended treatment to guide long‐term management of unprovoked VTE. …
benefit of extended treatment to guide long‐term management of unprovoked VTE. …
Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label …
JW Eikelboom, J Bosch, SJ Connolly… - European Heart …, 2022 - academic.oup.com
… The results of the COMPASS LTOLE study indicate that in patients with chronic CAD and/or
PAD, extended treatment with the combination of rivaroxaban 2.5 mg twice daily and aspirin …
PAD, extended treatment with the combination of rivaroxaban 2.5 mg twice daily and aspirin …
Rivaroxaban plus Aspirin for extended thromboprophylaxis in acutely ill medical patients: insights from the MARINER trial
… of symptomatic venous thromboembolism (VTE) … treatment with rivaroxaban plus aspirin
would be superior to use of neither rivaroxaban nor aspirin in preventing major thromboembolic …
would be superior to use of neither rivaroxaban nor aspirin in preventing major thromboembolic …
Broadening the categories of patients eligible for extended venous thromboembolism treatment
M Schindewolf, JI Weitz - Thrombosis and haemostasis, 2020 - thieme-connect.com
… treatment durations in these trials ranged from 4 weeks to 6 months, whereas longer treatment
… [12] [13] Overall, these trials revealed that longer treatment with VKAs reduced the risk of …
… [12] [13] Overall, these trials revealed that longer treatment with VKAs reduced the risk of …